Industry News
Avexa and CSIRO to collaborate
Melbourne-based Avexa (ASX:AVX) and the CSIRO have entered into a collaboration deal to discover new drugs for the treatment of human viral diseases. [ + ]
AtCor lists on ASX ahead of schedule
Shares in AtCor Medical (ASX:ACG), the developer and marketer of a device to measure cardiovascular function, began trading on the Australian Stock Exchange today at $0.65, 7.5 per cent above its issue price of $0.50. [ + ]
Pharmaxis sets US share price at $33
Drug developer Pharmaxis (ASX:PXS) has set the pricing of an underwritten public offering of 1,300,000 American Depositary Shares at a price of US$24.16 (AUD$33) per ADS. [ + ]
Dr Findlay's DNA casebook provides a Ripper yarn
Could an Australian gene-test company's uniquely sensitive new DNA fingerprinting technique finally finger history's most notorious serial murderer, London's Jack the Ripper? [ + ]
Tissue Therapies hopes new model can eliminate need for animal tests
If beauty is skin deep, the latest wrinkle from Brisbane biotech Tissue Therapies (ASX:TIS) should hold deep allure for cosmetics companies -- the company's researchers have developed a live-skin model with the same structure and properties as human skin. [ + ]
Portland Orthopaedics to raise up to $5 million, list on ASX
Hip replacement specialist Portland Orthopaedics has joined the growing list of companies who have lodged a prospectus to list on the ASX before Christmas. [ + ]
Vale Jamie Callachor
The NSW biotech community has been saddened by the loss of Jamie Callachor, who passed away on November 2. [ + ]
Sunshine Heart gets thumbs-up for Australian pilot study
Sunshine Heart (ASX:SHC) has received ethics committee approval to conduct implantations of its C-Pulse device in Australia at Southern Health Monash Medical Centre in Melbourne. [ + ]
Rockeby shares soar after bird flu test deal
Shares in Rockeby Biomed (ASX:RBY) quadrupled in value today after the company announced it has signed a deal with Thailand-based Pacific Biotech for the exclusive marketing and distribution rights in Europe, the Asia-Pacific and South Africa to two tests for avian flu. [ + ]
Epitan receives marketing approval for Zindaclin
Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has received approval from the Therapeutic Goods Administration (TGA) for the registration of anti-acne treatment Zindaclin. [ + ]
Qld to join synchrotron
The Queensland government and a consortium of Queensland universities will together invest AUD$5 million in the Melbourne-based Australian Synchrotron. [ + ]
BresaGen to make Psiron melanoma therapy
Sydney biotech Psiron (ASX:PSX) will be the first client for rejuvenated Adelaide biotechnology manufacturer BresaGen's new pilot production plant for therapeutics produced in mammalian cell cultures. [ + ]
Acrux terminates Napa licence
Acrux DDS, a wholly owned subsidiary of Melbourne-based Acrux (ASX:ACR), has terminated an exclusive licence agreement it signed in May 2005 with US firm Napa Biosciences. [ + ]
CyGenics acquires 51 per cent of BioCell
Cell therapy company CyGenics (ASX:CYN) has taken a 51 per cent controlling equity interest in cord blood stem cell banking business BioCell. [ + ]
Cytopia picks up $3m grant
Melbourne oncology drug developer Cytopia (ASX:CYT) has been offered a AUD$3 million federal government Commercial Ready grant to expand clinical development of its lead anti-cancer drug CYT997. [ + ]
